NAD+ and NMN sit on the same metabolic pathway: NMN is one step away from becoming NAD+, the coenzyme every cell uses for energy metabolism and DNA repair. The comparison is really about routes: take the precursor orally and let cells convert it, or supply the coenzyme itself directly. Each route has a different evidence profile, and neither has the clinical-outcome data the longevity conversation sometimes implies.
| Attribute | NAD+ | NMN |
|---|---|---|
| What it is | The coenzyme itself (nicotinamide adenine dinucleotide) | A direct precursor (nicotinamide mononucleotide), converted to NAD+ in cells |
| Typical route | Subcutaneous / IV in practitioner settings | Oral supplement |
| Human evidence | Thin formal trial record for injectable NAD+ itself | Small oral trials consistently show raised blood NAD+ levels, safely |
| Outcome data | Biomarker and anecdotal reports; no completed clinical programme | Biomarker changes more reliable than clinical endpoints so far |
| Regulatory picture | Not an approved medicine; no authorised indication | Contested supplement status in the US (FDA drug-preclusion); EU novel-food rules apply |
| Bioavailability question | Bypasses digestion entirely | Oral absorption and conversion efficiency still actively debated |
| In the Body Pharm catalogue | Yes (NAD+ 1000 pen) | No |
Cells make NAD+ continuously, mostly by recycling nicotinamide through the salvage pathway, and NMN is the last intermediate in that route. Oral NMN asks the gut and liver to absorb and convert it; injectable NAD+ skips the conversion question by supplying the finished coenzyme. The trade-off runs the other way on evidence: the oral-precursor route has more human studies behind it, while direct NAD+ administration has the cleaner delivery logic but the thinner formal record.
Precursor trials, of NMN and the related nicotinamide riboside, reliably raise blood NAD+ levels and look safe over the study durations. What they have not yet shown consistently is hard clinical outcomes; the endpoint data lag behind the biomarker data. Injectable NAD+ has even less formal trial coverage, and its use in wellness and practitioner settings runs well ahead of its published evidence.
NMN’s status is contested: the US FDA has taken the position that NMN is precluded from sale as a dietary supplement because it was studied as a drug candidate, and in the EU it falls under novel-food authorisation rules. NAD+ itself is not an approved medicine anywhere and has no authorised injectable indication. Neither compound’s regulatory story matches the confidence of its marketing.
No head-to-head human trial answers this. Oral NMN has more evidence that it raises NAD+ levels; injectable NAD+ has the more direct delivery route but a thinner trial record. Neither has demonstrated superior clinical outcomes.
The rationale is bypassing oral absorption and conversion, which remain debated for NMN. That is a delivery argument, not an outcomes claim; the formal evidence for injectable NAD+ is limited.
Not banned, but contested: the US FDA considers it precluded from dietary-supplement status, and in the EU it requires novel-food authorisation. Enforcement and availability vary by market.
No. Lifespan extension has been shown in some animal models for NAD+-boosting strategies, but no human lifespan or healthspan outcome has been demonstrated for either compound.
This page is educational and intended for research and informational use only. It is not medical advice, a treatment recommendation, or dosing guidance, and it makes no promises about outcomes. Where a compound has held a marketing authorisation, approved medicines are supplied only through licensed pharmacies with a prescription. Body Pharm EU supplies research-grade materials for laboratory use, not approved medicines, and nothing here should be read as a substitute for advice from a qualified healthcare professional.
This is not a comparison between competing products. NAD+ is the coenzyme; NMN is one of the molecules the body converts toward it. Framing them as rivals is a category error, and it is the framing almost every page in this space uses.
Effects of nicotinamide mononucleotide on glucose and lipid metabolism in adults: systematic review and meta-analysis of RCTs. PMID 39531138; Efficacy and safety of β-NMN in healthy middle-aged adults: randomised, dose-dependent trial. PMID 36482258; Improved physical performance parameters in patients taking NMN: systematic review of RCTs. PMC11365583
NAD+ participates directly in cellular energy metabolism as a coenzyme in redox reactions (see the NAD+ overview). NMN sits on the salvage pathway and is converted toward NAD+.
Asking which is “better” is like asking whether flour beats bread. The real question is whether supplying the precursor and letting conversion happen is preferable to supplying the destination molecule directly, and that is an open question, not a settled one.
NAD+ is a comparatively large molecule, and poor oral absorption is the standard explanation for why NAD+ products, including our NAD+ 1000 pen, are presented as injectable or intravenous. NMN is smaller and is routinely formulated orally.
This is why the human trial literature is overwhelmingly about NMN rather than NAD+: the precursor is the one you can practically put in a capsule and run a trial with.
Clear on one point, equivocal on another.
The biomarker moves. NMN supplementation produced dose-dependent increases in cellular NAD+ in rodents and in humans, across trials using 150 to 1200 mg/day.
The outcomes are inconsistent. A meta-analysis of randomised controlled trials found no significant benefit on fasting glucose, fasting insulin, glycated haemoglobin or lipid profile across short-term supplementation. A separate systematic review reported improvements in physical performance measures such as six-minute walk distance, with larger NAD+ increases associated with larger improvements.
The honest summary: the thing being measured as a proxy responds reliably, and what the proxy stands in for does not respond uniformly. That is more useful than either “proven” or “debunked”, and it is the same distinction that organises peptides for longevity.
Nothing has compared injected NAD+ against oral NMN in the same study. Given the route difference that would be a hard trial to design well, and its absence is why the “which is better” question has no evidence-based answer.
NAD+ holds no marketing authorisation as a medicine for this use. NMN is generally marketed as a food supplement: a different regulatory framework again, with different requirements and no medicines assessment behind it.
Related: NAD+ vs nicotinamide riboside, mitochondrial peptides.
We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy